No abstract available
Keywords:
ABL kinase inhibitor; COVID-19; Imatinib; SARS-CoV-2; Treatment.
MeSH terms
-
Adult
-
Betacoronavirus / pathogenicity*
-
Biomarkers / blood
-
C-Reactive Protein / metabolism
-
COVID-19
-
Coronavirus Infections / diagnostic imaging
-
Coronavirus Infections / drug therapy*
-
Coronavirus Infections / pathology
-
Coronavirus Infections / virology
-
Drug Combinations
-
Female
-
Humans
-
Hydroxychloroquine / administration & dosage
-
Imatinib Mesylate / therapeutic use*
-
Lopinavir / administration & dosage
-
Lung / diagnostic imaging
-
Lung / drug effects*
-
Lung / pathology
-
Lung / virology
-
Pandemics
-
Pneumonia, Viral / diagnostic imaging
-
Pneumonia, Viral / drug therapy*
-
Pneumonia, Viral / pathology
-
Pneumonia, Viral / virology
-
Protein Kinase Inhibitors / therapeutic use*
-
Ritonavir / administration & dosage
-
SARS-CoV-2
-
Tomography, X-Ray Computed
-
Treatment Outcome
Substances
-
Biomarkers
-
Drug Combinations
-
Protein Kinase Inhibitors
-
lopinavir-ritonavir drug combination
-
Lopinavir
-
Hydroxychloroquine
-
Imatinib Mesylate
-
C-Reactive Protein
-
Ritonavir